Breast Cancer: Everolimus
(asked on 27th October 2016) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, on what evidence the Clinical Priorities Advisory Board based its decision to not fund the use of Afinitor for the treatment of breast cancer.
This question was answered on 3rd November 2016
The Clinical Priorities Advisory Group has not considered Afinator for the treatment of breast cancer.
Afinitor is one of four breast cancer treatments currently available through the Cancer Drugs Fund (CDF), where certain criteria apply. Afinitor will remain available through the CDF while it is being reappraised by the National Institute for Health and Care Excellence as part of the transition to the new CDF model.